Please use this identifier to cite or link to this item:
Title: Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
Author: Narváez García, Francisco Javier
Díaz-Torné, César
Juanola, Xavier
Geli, C.
Llobet, Josep Maria
Nolla Solé, Joan Miquel
Díaz-López, C.
Keywords: Artritis
Issue Date: 2009
Publisher: BMJ Group
Abstract: Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFα) inhibitors or anakinra.1–6 However, this therapeutic arsenal is unable to control the disease in all patients.#N##N#Recently, rituximab, a chimeric anti-CD20 monoclonal antibody, has been successfully used in two patients with refractory adult-onset Still’s disease.7 As the similarity of clinical and laboratory features present in SOJIA and adult-onset Still’s disease implies that these conditions have similar …
Note: Reproducció digital del document publicat a:
It is part of: Annals of the Rheumatic Diseases, 2009, vol. 68, num. 4, p. 607-608
Related resource:
ISSN: 0003-4967
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
580828.pdf117.12 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.